AstraZeneca has moved a step closer to joining the fiercely competitive field of weight-loss treatments after data showed patients lost nearly 12 per cent of their body weight in a mid-stage clinical trial.
The Anglo-Swedish group said participants in a phase 2 trial shed 11.8 per cent of their weight after 36 weeks on elecoglipron, a daily GLP-1 pill. Those who used the drug for 26 weeks lost 10.5 per cent of their weight, compared with 0.6 per cent on a placebo.
Patients in the trial experienced the common gastrointestinal challenges — nausea, diarrhoea and vomiting — associated with the GLP-1 class of drugs, AstraZeneca said.
您已阅读17%（634字），剩余83%（3045字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。